ENB 838
Alternative Names: ENB-838Latest Information Update: 04 Jan 2024
At a glance
- Originator Engine Biosciences
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Colorectal cancer; Lung cancer; Ovarian cancer; Solid tumours
Most Recent Events
- 04 Jan 2024 ENB 838 is available for licensing as of 04 Jan 2024. https://www.enginebio.com/partnering/
- 27 Nov 2023 Early research in Colorectal cancer in Singapore (Engine Biosciences pipeline, November 2023)
- 27 Nov 2023 Early research in Lung cancer in Singapore (Engine Biosciences pipeline, November 2023)